APA (7th ed.) Citation

ASV, S., M, V., K, W., I, S., R, H., M, G., . . . E, H. (2022). Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months. The Journal of infectious diseases, 227(1), 71. https://doi.org/10.1093/infdis/jiac407

Chicago Style (17th ed.) Citation

ASV, Stuart, et al. "Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months." The Journal of Infectious Diseases 227, no. 1 (2022): 71. https://doi.org/10.1093/infdis/jiac407.

MLA (9th ed.) Citation

ASV, Stuart, et al. "Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months." The Journal of Infectious Diseases, vol. 227, no. 1, 2022, p. 71, https://doi.org/10.1093/infdis/jiac407.